Scientists explored the critical oncogenic pathways controlled by DNAJB1-PRKACA using patient-derived fibrolamellar carcinoma models, engineered systems, and patient samples.
[nan]
Home Newsletters Hepatic Cell News DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated...
